3M Company Stock Price and Value Analysis

3M Company (NYSE:MMM) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold 3M Company to reach your target.

Target type

MMM Free Cash Flow Trend

Free Cash Flow trendline for MMM
Free Cash Flow trendline for 3M Company
CSV

Based on historical returns, we believe that 3M Company can grow its free cash at a rate of about 10%. That's positive!

AdvantagesDisadvantages
  • This stock is available at a great discount!
  • This company is a well-established bedrock.
  • This company is making money at a great rate!
  • This company has wild ups and downs.
  • This company has a low dividend yield.

Inside the MMM Numbers

MMM Price
(3M Company stock price per share)
$177.99
[?] MMM Fair Price
(based on intrinsic value)
$309.10
[?] MMM Safety Price (based on a variable margin of safety) $262.74
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 31% higher than other Healthcare stocks
[?] PE Ratio versus Industry 100% higher than other Medical Devices stocks
[?] Cash Yield 6.96%
[?] Free Cash Flow Jitter 37%
[?] Dividend Yield 1.72% (tax impact)
Shares Shorted 9,968,964

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 9,968,964 shares shorted. With 515,866,636 shares available for purchase and an average trading volume over the past 10 trading days of 3,254,340, it would take at least 3.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 66740 2,824
2008 66740 3,087
2009 66740 3,676
2010 66740 3,952
2011 66740 4,031
2012 66740 4,034
2013 66740 4,513
2014 66740 5,204
2015 66740 4,924
2016 66740 5,157
2017 66740 4,758
2018 66740 4,974
2019 66740 5,564
2020 66740 6,599
2021 66740 5,903
2022 66740 3,965
2023 66740 5,047
2024 66740 289
2025 66740 894

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 18 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $100,035 million against net income of $82,353 million, or 1.21 times. Net income was negative in 1 of the 19 years, and those years are left out of the ratio.

In 2025, operating cash flow was 0.71 times net income, compared with 1.28 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $910 million, 39.5% of operating cash flow of $2,306 million, which leaves an estimated $1,396 million after capex. Across the 19 years with reported capex, it averaged 25.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 0.71, below 0.80, so under 80% of reported net income arrived as operating cash and at least 0.25 under the 1.28 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 4,096 4,246 1,422 1.04
2008 3,460 4,533 1,471 1.31
2009 3,193 4,941 903 1.55
2010 4,085 5,174 1,091 1.27
2011 4,283 5,284 1,379 1.23
2012 4,444 5,300 1,484 1.19
2013 4,659 5,817 1,665 1.25
2014 4,956 6,626 1,493 1.34
2015 4,833 6,420 1,461 1.33
2016 5,050 6,662 1,420 1.32
2017 4,858 6,240 1,373 1.28
2018 5,349 6,439 1,577 1.20
2019 4,517 7,070 1,699 1.57
2020 5,449 8,113 1,501 1.49
2021 5,921 7,454 1,603 1.26
2022 5,777 5,591 1,749 0.97
2023 -6,995 6,680 1,615 n/a
2024 4,173 1,819 1,181 0.44
2025 3,250 2,306 910 0.71

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $43,151 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $29,022 million, 67.3% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 8 of those 10 years.

In 9 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $21,181 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $4,813 million, 538.1% of estimated free cash flow of $894 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 5,157 2,678 3,753 6,431 124.7%
2017 4,758 2,803 2,068 4,871 102.4%
2018 4,974 3,193 4,870 8,063 162.1%
2019 5,564 3,316 1,407 4,723 84.9%
2020 6,599 3,388 368 3,756 56.9%
2021 5,903 3,420 2,199 5,619 95.2%
2022 3,965 3,369 1,464 4,833 121.9%
2023 5,047 3,311 33 3,344 66.3%
2024 289 1,982 1,801 3,783 1308.1%
2025 894 1,562 3,251 4,813 538.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $24,462 million in 2007 and $24,948 million in 2025, a compound annual growth rate of 0.1% over 18 years.

Revenue rose 1.5% from 2024 to 2025.

Our estimated free cash flow was $894 million in 2025, 3.6% of revenue. In 2007 the estimated margin was 11.5%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 24,462 2,824 11.5%
2008 25,269 3,087 12.2%
2009 23,123 3,676 15.9%
2010 26,662 3,952 14.8%
2011 29,611 4,031 13.6%
2012 29,904 4,034 13.5%
2013 30,871 4,513 14.6%
2014 31,821 5,204 16.4%
2015 30,274 4,924 16.3%
2016 30,109 5,157 17.1%
2017 31,657 4,758 15.0%
2018 32,765 4,974 15.2%
2019 32,136 5,564 17.3%
2020 32,184 6,599 20.5%
2021 35,355 5,903 16.7%
2022 26,161 3,965 15.2%
2023 24,610 5,047 20.5%
2024 24,575 289 1.2%
2025 24,948 894 3.6%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $5,235 million against total liabilities of $32,986 million, or 15.9% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 87.4% of total assets in 2025, compared with 60.1% in 2008, an increase of 27.4 percentage points.

Stockholders equity was $4,747 million in 2025, compared with $10,304 million in 2008, a fall of 53.9%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 3.9% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 25,793 1,849 15,489 10,304
2009 27,250 3,040 13,948 13,302
2010 30,156 3,377 14,139 16,017
2011 31,616 2,219 15,754 15,862
2012 33,876 2,883 15,836 18,040
2013 33,304 2,581 15,881 17,948
2014 31,374 1,897 18,346 13,142
2015 32,883 1,798 21,415 11,468
2016 32,906 2,398 22,563 10,343
2017 37,987 3,053 26,365 11,622
2018 36,500 2,853 26,652 9,848
2019 44,659 n/a 34,533 10,126
2020 47,344 4,634 34,413 12,931
2021 47,072 4,564 31,955 15,117
2022 46,455 3,655 31,685 14,770
2023 50,580 5,933 45,712 4,868
2024 39,868 5,600 35,974 3,894
2025 37,733 5,235 32,986 4,747

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $177.99, our model's value equals that price if free cash flow grows an average of 2.6 percent a year over the 10 projection years. Our model assumes 10.4 percent a year for this stock, so the price implies growth of 2.6 percent, which is below the 10.4 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $6,400 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $142.39 -0.6%
Current price $177.99 2.6%
20 percent above the current price $213.59 5.2%
Our model (stored fair price) $309.10 10.4%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Free cash flow was positive in all 19 fiscal years we have for 3M Company under its current SEC filer.

At $177.99, the stock is under our safe value of $262.74, against a fair value estimate of $309.10.

3M Company's average free cash flow fell sharply, from $3,195 million in its earliest three years to $2,077 million in its latest three.

Free cash flow is volatile from year to year, with a variability measure of 37%.

3M Company pays a dividend yield of 1.72%.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 31% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to 3M Company, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
3M Company (MMM) 91,973 26.6 1.7% 7.0% 42% below
Boston Scientific Corporation (BSX) 60,849 17.7 - 1.9% 49% above
ResMed (RMD) 33,143 21.5 1.0% 1.2% 81% above
DexCom (DXCM) 29,582 31.2 - 0.1% 864% above
West Pharmaceutical Services (WST) 27,189 43.8 0.2% 0.6% 320% above
Baxter International (BAX) 13,135 - 0.2% 11.4% 61% below
Penumbra (PEN) 12,578 80.4 - - 781% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 66740.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: MMM annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in MMM

Does 3M Company have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: MMM

This example shows how we apply the Trendshare checklist to MMM: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 177.99
    • Market cap: $92B
    • EPS: 6.7
  2. Step 2 — Valuation checks

    • P/E: 26.566
    • FCF yield: 7.0%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.